BridgeBio Pharma EBITDA Margin 2018-2024 | BBIO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for BridgeBio Pharma (BBIO) over the last 10 years. The current EBITDA margin for BridgeBio Pharma as of September 30, 2024 is .
| BridgeBio Pharma EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$0.22B |
$-0.54B |
-246.79% |
| 2024-06-30 |
$0.22B |
$-0.50B |
-230.14% |
| 2024-03-31 |
$0.22B |
$-0.47B |
-216.44% |
| 2023-12-31 |
$0.01B |
$-0.60B |
-6010.00% |
| 2023-09-30 |
$0.01B |
$-0.55B |
-5530.00% |
| 2023-06-30 |
$0.01B |
$-0.52B |
-8733.33% |
| 2023-03-31 |
$0.08B |
$-0.46B |
-588.46% |
| 2022-12-31 |
$0.08B |
$-0.51B |
-648.72% |
| 2022-09-30 |
$0.09B |
$-0.54B |
-608.99% |
| 2022-06-30 |
$0.09B |
$-0.56B |
-619.78% |
| 2022-03-31 |
$0.07B |
$-0.58B |
-811.27% |
| 2021-12-31 |
$0.07B |
$-0.57B |
-827.54% |
| 2021-09-30 |
$0.06B |
$-0.53B |
-953.57% |
| 2021-06-30 |
$0.06B |
$-0.51B |
-816.13% |
| 2020-09-30 |
$0.02B |
$-0.43B |
-1931.82% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
